SCHEMBL5029661

SCHEMBL5029661

Cc1ccc(-c2nc(N)nc(Nc3ccc(CCCO)cc3)c2F)cc1S(N)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP3 O14638 9/20 0.47
▸ TP53 P04637 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ GPR174 Q9BXC1 1/20 0.43
▸ BACE1 P56817 1/20 0.42
▸ PLK4 O00444 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ DAPK3 O43293 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ PAK4 O96013 1/20 0.41
▸ CHEK2 O96017 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ ERBB2 P04626 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14995676 0.85 CA2 (0.51) ENPP3CA2CA9CDK1CDK2
SCHEMBL14995675 0.82 STAT6 (0.39) KMT2AMAPTCA2CA9CDK1
SCHEMBL4006171 0.77 SYK (0.65) PLK4AURKAPDPK1DAPK3JAK2
SCHEMBL3999707 0.74 SYK (0.64) PLK4AURKAPDPK1DAPK3JAK2
SCHEMBL4002720 0.68 SYK (0.64) PLK4AURKAPDPK1DAPK3JAK2
SCHEMBL4000659 0.67 AURKA (0.63) PLK4AURKAPDPK1DAPK3JAK2
SCHEMBL7169031 0.66 MEN1 (0.49) TP53KMT2AMAPTBACE1SYK
SCHEMBL4008183 0.66 AURKA (0.69) PLK4AURKAPDPK1DAPK3JAK2
SCHEMBL5027956 0.66 EGFR (0.42) ENPP3TP53THRBKMT2AMAPT
SCHEMBL4001420 0.66 AURKA (0.59) CA2CA9AURKAJAK2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904457-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY Rigel Pharmaceuticals, Inc. (US) 2008-04-02 — — EP disclosed
WO-2006133426-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2006-12-14 — — WO disclosed
Send feedback